[go: up one dir, main page]

MX2011006603A - Compuestos utiles para inhibir chk1. - Google Patents

Compuestos utiles para inhibir chk1.

Info

Publication number
MX2011006603A
MX2011006603A MX2011006603A MX2011006603A MX2011006603A MX 2011006603 A MX2011006603 A MX 2011006603A MX 2011006603 A MX2011006603 A MX 2011006603A MX 2011006603 A MX2011006603 A MX 2011006603A MX 2011006603 A MX2011006603 A MX 2011006603A
Authority
MX
Mexico
Prior art keywords
compounds useful
inhibiting chk1
chk1
inhibiting
useful
Prior art date
Application number
MX2011006603A
Other languages
English (en)
Inventor
Francine S Farouz
Ryan Coatsworth Holcomb
Ramesh Kasar
Steven Scott Myers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2011006603A publication Critical patent/MX2011006603A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona un compuesto de aminopirazol, o una sal farmacéuticamente aceptable del mismo o un solvato de la sal, que inhibe Chk1 y es útil en el tratamiento de cáncer.
MX2011006603A 2008-12-17 2009-12-10 Compuestos utiles para inhibir chk1. MX2011006603A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17
PCT/US2009/067437 WO2010077758A1 (en) 2008-12-17 2009-12-10 Compounds useful for inhibiting chk1

Publications (1)

Publication Number Publication Date
MX2011006603A true MX2011006603A (es) 2011-09-27

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006603A MX2011006603A (es) 2008-12-17 2009-12-10 Compuestos utiles para inhibir chk1.

Country Status (37)

Country Link
EP (1) EP2379532B1 (es)
JP (1) JP5705743B2 (es)
KR (1) KR101301777B1 (es)
CN (1) CN102245597B (es)
AR (1) AR074471A1 (es)
AU (1) AU2009333433B2 (es)
BR (1) BRPI0922468A2 (es)
CA (1) CA2746423C (es)
CL (1) CL2011001463A1 (es)
CO (1) CO6382122A2 (es)
CR (1) CR20110339A (es)
CY (1) CY1113930T1 (es)
DK (1) DK2379532T3 (es)
DO (1) DOP2011000185A (es)
EA (1) EA018118B1 (es)
EC (1) ECSP11011136A (es)
ES (1) ES2401558T3 (es)
HN (1) HN2011001446A (es)
HR (1) HRP20130167T1 (es)
IL (1) IL213160A (es)
JO (1) JO2886B1 (es)
MA (1) MA32901B1 (es)
MX (1) MX2011006603A (es)
MY (1) MY156998A (es)
NZ (1) NZ593440A (es)
PA (1) PA8850801A1 (es)
PE (1) PE20120077A1 (es)
PL (1) PL2379532T3 (es)
PT (1) PT2379532E (es)
RS (1) RS52739B (es)
SG (1) SG172222A1 (es)
SI (1) SI2379532T1 (es)
TN (1) TN2011000298A1 (es)
TW (1) TWI436996B (es)
UA (1) UA101998C2 (es)
WO (1) WO2010077758A1 (es)
ZA (1) ZA201103946B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
AR083575A1 (es) * 2010-11-08 2013-03-06 Lilly Co Eli Aminopirazoles para inhibir la proteinquinasa chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
TWI627168B (zh) * 2015-12-07 2018-06-21 美國禮來大藥廠 (s)-乳酸鹽
BR112018011203A2 (pt) 2015-12-15 2018-11-21 Lilly Co Eli terapia de combinação para câncer
EP3411036B1 (en) * 2016-02-04 2021-12-29 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN114746413B (zh) * 2019-11-29 2024-02-23 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
KR20230115988A (ko) 2020-11-30 2023-08-03 스미토모 파마 가부시키가이샤 5-헤테로아릴-1h-피라졸-3-아민 유도체
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
IL308759A (en) 2021-05-27 2024-01-01 Boundless Bio Inc Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
EP4455134A4 (en) 2021-12-24 2025-10-08 Sumitomo Pharma Co Ltd 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON
JP7546104B2 (ja) * 2022-05-27 2024-09-05 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬
JPWO2023229032A1 (es) * 2022-05-27 2023-11-30
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
GB202403910D0 (en) 2024-03-19 2024-05-01 Benovental Cambridge Ltd New processes and intermediates for pharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
JP2006528661A (ja) * 2003-07-25 2006-12-21 ファイザー・インク アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Also Published As

Publication number Publication date
CR20110339A (es) 2011-09-14
TW201029994A (en) 2010-08-16
KR20110084539A (ko) 2011-07-25
PL2379532T3 (pl) 2013-07-31
HN2011001446A (es) 2013-08-05
CA2746423A1 (en) 2010-07-08
JP2012512249A (ja) 2012-05-31
CO6382122A2 (es) 2012-02-15
JO2886B1 (en) 2015-03-15
BRPI0922468A2 (pt) 2020-08-04
HRP20130167T1 (hr) 2013-03-31
ECSP11011136A (es) 2011-07-29
CL2011001463A1 (es) 2012-01-20
EP2379532A1 (en) 2011-10-26
PA8850801A1 (es) 2010-07-27
IL213160A (en) 2013-12-31
CN102245597A (zh) 2011-11-16
UA101998C2 (ru) 2013-05-27
EP2379532B1 (en) 2013-02-20
JP5705743B2 (ja) 2015-04-22
PT2379532E (pt) 2013-03-25
AR074471A1 (es) 2011-01-19
HK1160110A1 (en) 2012-08-10
DK2379532T3 (da) 2013-03-18
WO2010077758A1 (en) 2010-07-08
RS52739B (sr) 2013-08-30
SI2379532T1 (sl) 2013-05-31
IL213160A0 (en) 2011-07-31
AU2009333433B2 (en) 2012-06-14
CA2746423C (en) 2014-01-14
CN102245597B (zh) 2014-04-16
PE20120077A1 (es) 2012-02-06
MA32901B1 (fr) 2011-12-01
EA201170834A1 (ru) 2011-12-30
MY156998A (en) 2016-04-15
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
EA018118B1 (ru) 2013-05-30
DOP2011000185A (es) 2017-12-15
CY1113930T1 (el) 2016-07-27
SG172222A1 (en) 2011-07-28
KR101301777B1 (ko) 2013-08-30
AU2009333433A1 (en) 2011-06-30
ZA201103946B (en) 2012-10-31
TWI436996B (zh) 2014-05-11
ES2401558T3 (es) 2013-04-22

Similar Documents

Publication Publication Date Title
JO2886B1 (en) Useful compounds in the inhibition of CHK1
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TN2012000622A1 (en) Combinations of kinase inhibitors for the treatment of cancer
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
MX2009009786A (es) Inhibidores de la via de hedgehog.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
PT2120932E (pt) Derivados de indazol como inibidores da quinase para tratamento do cancro
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
TW200738725A (en) Unsaturated mTOR inhibitors
TN2011000293A1 (en) Protein kinase inhibitors
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
PH12014500215B1 (en) Notch pathway signaling inhibitor compound
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
UA100544C2 (ru) Гидроксилированный пиримидилциклопентан как ингибитор протеинкиназы акт
WO2010039668A3 (en) Inhibitors of cyclin kinase inhibitor p21
MX2009012233A (es) Compuestos de triazolil aminopirimidina.
UA99612C2 (en) Inhibitors of the hedgehog pathway
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration